The chemokine CXCL10 correlates with clinical response to ruxolitinib cream in vitiligo patients, according to the Phase 2 randomized TRuE-V mechanism-of-action study, published online October 13, 2026, in the Journal of Investigative Dermatology.

The work comes from Thierry Passeron, Mark Lebwohl, Charles Lynde and colleagues, with the full author team spanning clinical and industry researchers including Cynthia Timmers, Babak Soltanalizadeh and Deanna Kornacki.

Why does a biomarker paper matter when the drug is already approved and in your dispensary? Because repigmentation on JAK inhibition remains frustratingly variable. Some patients respond convincingly. Others stall after months of twice-daily application. A pretreatment predictor, even a partial one, gives you a way to set expectations before the first follow-up visit.

What did the study measure?

The TRuE-V mechanism-of-action program was a randomized Phase 2 design, run alongside the pivotal work that established ruxolitinib cream in vitiligo. This substudy asked a different question: not "does it work?" but "can we see who it works in?"

The investigators focused on CXCL10, a chemokine already implicated in vitiligo pathogenesis. It drives recruitment of CXCR3-expressing T cells to the skin, and those tissue-resident T cells are the effector arm attacking melanocytes. Ruxolitinib, a JAK1/JAK2 inhibitor, sits directly upstream of the signaling that produces this inflammatory cascade — which makes CXCL10 a mechanistically plausible readout, not just a statistical association.

The published analysis reports that CXCL10 levels track with clinical response to treatment. In practical terms: the chemokine behaves as a pharmacodynamic marker, moving with the disease activity that ruxolitinib cream is meant to suppress.

What does this change for practicing dermatologists?

Right now, nothing at the point of care. There is no commercial CXCL10 assay you can order for a vitiligo patient next week. The finding is translational, not diagnostic.

But it changes the trajectory of the field in three concrete ways:

• Patient selection research. A validated biomarker could eventually spare non-responders months of ineffective topical therapy and steer them toward combination approaches earlier.

• Trial enrichment. Future Phase 2 and 3 vitiligo trials can use CXCL10 to stratify or select enrollees, sharpening the signal-to-noise ratio that has made vitiligo endpoints notoriously hard to read.

• Mechanistic confirmation. The data reinforce that vitiligo progression is chemokine-driven and locally measurable — supporting the rationale for JAK inhibition and, by extension, for combination strategies pairing ruxolitinib cream with agents targeting complementary pathways.

Context for the clinic

Ruxolitinib cream remains the flagship topical JAK option in vitiligo, and the TRuE-V program is the evidentiary backbone behind it. This mechanism-of-action substudy adds a layer beneath the efficacy data: a molecular handle on why some skin repigments and some does not.

Passeron's group has been consistent in pushing vitiligo from a clinically descriptive disease toward a measurable, biomarker-informed one. This paper is another step in that direction.

Expect the next wave of studies to test whether baseline CXCL10 — measured in lesional skin or, ideally, in easier-to-obtain samples — can prospectively predict response. If it can, treatment conversations in vitiligo shift from educated guesswork toward stratified therapy.